$ITCI
Intra-Cellular Therapies, Inc. Stock $itci

$itci Overview Financials Valuation SEC Filings Company Website

2013 Q4 Form 10-Q Financial Statement

#000119312513427801 Filed on November 05, 2013

Income Statement

Concept	2013 Q4	2013 Q3	2012 Q3
Revenue	$827.5K	$668.0K	$377.9K
YoY Change	23.51%	76.75%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.730M	$1.300M	$800.0K
YoY Change	143.75%	62.5%
% of Gross Profit
Research & Development	$6.130M	$4.158M	$1.797M
YoY Change	1078.85%	131.32%
% of Gross Profit
Depreciation & Amortization	$0.00	$4.729K	$10.00K
YoY Change	-100.0%	-52.71%
% of Gross Profit
Operating Expenses	$8.860M	$4.158M	$1.797M
YoY Change	440.24%	131.32%
Operating Profit		-$4.785M	-$2.222M
YoY Change		115.4%
Interest Expense	$10.00K	$131.9K	$10.00K
YoY Change	-105.56%	1218.88%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$8.020M	-$4.910M	-$2.210M
YoY Change	597.39%	122.17%
Income Tax	$20.00K	$0.00	$8.230K
% Of Pretax Income
Net Earnings	-$8.041M	-$4.912M	-$2.220M
YoY Change	593.17%	121.24%
Net Earnings / Revenue	-971.66%	-735.32%	-587.44%
Basic Earnings Per Share		-$0.42	-$0.40
Diluted Earnings Per Share	-$175.4K	-$0.42	-$0.40
COMMON SHARES
Basic Shares Outstanding	22.13M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2013 Q4	2013 Q3	2012 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$37.20M	$46.10M
YoY Change	94.76%
Cash & Equivalents	$35.15M	$44.07M	$3.835M
Short-Term Investments	$2.000M	$2.000M
Other Short-Term Assets	$800.0K	$800.0K
YoY Change	300.0%
Inventory
Prepaid Expenses
Receivables	$336.3K	$251.3K
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$38.25M	$47.13M
YoY Change	94.81%
LONG-TERM ASSETS
Property, Plant & Equipment	$68.27K	$75.70K
YoY Change	17.17%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$131.6K	$130.8K
YoY Change	0.61%
Total Long-Term Assets	$199.8K	$206.5K
YoY Change	5.72%
TOTAL ASSETS
Total Short-Term Assets	$38.25M	$47.13M
Total Long-Term Assets	$199.8K	$206.5K
Total Assets	$38.45M	$47.34M
YoY Change	93.96%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.395M	$4.027M
YoY Change	8059.65%
Accrued Expenses	$3.400M	$3.300M
YoY Change	209.09%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$6.834M	$7.775M
YoY Change	140.67%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$6.834M	$7.775M
Total Long-Term Liabilities	$0.00	$0.00
Total Liabilities	$6.800M	$7.800M
YoY Change	142.86%
SHAREHOLDERS EQUITY
Retained Earnings	-$57.56M	-$49.52M
YoY Change	87.53%
Common Stock	$2.216K	$2.213K
YoY Change	51.78%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$31.62M	$39.56M
YoY Change
Total Liabilities & Shareholders Equity	$38.45M	$47.34M
YoY Change	93.96%

Cashflow Statement

Concept	2013 Q4	2013 Q3	2012 Q3
OPERATING ACTIVITIES
Net Income	-$8.041M	-$4.912M	-$2.220M
YoY Change	593.17%	121.24%
Depreciation, Depletion And Amortization	$0.00	$4.729K	$10.00K
YoY Change	-100.0%	-52.71%
Cash From Operating Activities	-$8.630M	-$4.760M	-$5.590M
YoY Change	109.47%	-14.85%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	-$20.00K	-$10.00K
YoY Change		100.0%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$1.750M
YoY Change	-100.0%	-100.0%
Cash From Investing Activities	$0.00	-$20.00K	$1.740M
YoY Change	-100.0%	-101.15%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-290.0K	40.52M	10.00K
YoY Change	-101.91%	405100.0%
NET CHANGE
Cash From Operating Activities	-8.630M	-4.760M	-5.590M
Cash From Investing Activities	0.000	-20.00K	1.740M
Cash From Financing Activities	-290.0K	40.52M	10.00K
Net Change In Cash	-8.920M	35.74M	-3.840M
YoY Change	-175.53%	-1030.73%
FREE CASH FLOW
Cash From Operating Activities	-$8.630M	-$4.760M	-$5.590M
Capital Expenditures	$0.00	-$20.00K	-$10.00K
Free Cash Flow	-$8.630M	-$4.740M	-$5.580M
YoY Change	109.47%	-15.05%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2013Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	22134647	shares
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	13693215
CY2012Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3835190
CY2012Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	14599612	shares
CY2012Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	22134647	shares
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.3802
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1707114	shares
CY2012Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2012Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2012Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3220417
CY2012Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	47678924
CY2012Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	404656
CY2012Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	41608
CY2012Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0
CY2012Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2839595
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	16984085
CY2012Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	726657
CY2012Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-30696299
CY2012Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1666674
CY2012Q4	us-gaap	Common Stock Value CommonStockValue	1460
CY2012Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	19823680
CY2012Q4	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	0
CY2012Q4	us-gaap	Assets Current AssetsCurrent	19634659
CY2012Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	130755
CY2012Q4	us-gaap	Assets Assets	19823680
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	15645528
CY2012Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	1200000
CY2012Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	300429
CY2012Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3278683
CY2012Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	188702
CY2012Q4	us-gaap	Certificates Of Deposit At Carrying Value CertificatesOfDepositAtCarryingValue	3500000
CY2012Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	58266
CY2013Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	14599612	shares
CY2013Q3	us-gaap	Business Acquisition Percentage Of Voting Interests Acquired BusinessAcquisitionPercentageOfVotingInterestsAcquired	1.00	pure
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1118156	shares
CY2013Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	22134647	shares
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.9410
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1462380	shares
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	1.9410
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	1462380	shares
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	1.5801
CY2013Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2013Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2013Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3236238
CY2013Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	89082858
CY2013Q3	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	2571126
CY2013Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	4027097
CY2013Q3	us-gaap	Common Stock Value CommonStockValue	2213
CY2013Q3	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0
CY2013Q3	us-gaap	Liabilities Current LiabilitiesCurrent	7774662
CY2013Q3	us-gaap	Stockholders Equity StockholdersEquity	39561384
CY2013Q3	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	759757
CY2013Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-49523687
CY2013Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	416682
CY2013Q3	us-gaap	Certificates Of Deposit At Carrying Value CertificatesOfDepositAtCarryingValue	2000000
CY2013Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	75700
CY2013Q3	ck0001567514	Business Combination Equity Interest Exchange Ratio BusinessCombinationEquityInterestExchangeRatio	0.5	pure
	dei	Entity Registrant Name EntityRegistrantName	Intra-Cellular Therapies, Inc.
	dei	Amendment Flag AmendmentFlag	false
	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2013
	dei	Document Type DocumentType	10-Q
	dei	Document Period End Date DocumentPeriodEndDate	2013-09-30
	dei	Entity Central Index Key EntityCentralIndexKey	0001567514
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
CY2013Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	47336046
CY2013Q3	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	0
CY2013Q3	us-gaap	Assets Current AssetsCurrent	47129591
CY2013Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	130755
CY2013Q3	us-gaap	Assets Assets	47336046
CY2013Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	44072012
CY2013Q3	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	21200000
CY2013Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	251291
CY2013Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3311938
CY2013Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	806288
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.43
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.80	pure
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.43
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y6M
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	247600	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y2M12D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod	P10Y
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	7737250	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	3.2600
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00	pure
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-13963457
	us-gaap	Subsidiary Or Equity Method Investee Cumulative Percentage Ownership After All Transactions SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions	1.00	pure
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.6470
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	2667	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y10M24D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P5Y6M
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	489667	shares
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div> <p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"> <b>Concentration of Credit Risk</b></p> <p style="MARGIN-TOP: 6pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"> Cash equivalents are held with major financial institutions in the United States. Certificates of deposit held with banks may exceed the amount of insurance provided on such deposits. Generally, these deposits may be redeemed upon demand and, therefore, bear minimal risk.</p> </div>
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	2.9725
	us-gaap	Use Of Estimates UseOfEstimates	<div> <p style="MARGIN-TOP: 6pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"> <b>Use of Estimates</b></p> <p style="MARGIN-TOP: 6pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"> The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Although actual results could differ from those estimates, management does not believe that such differences would be material.</p> </div>
	us-gaap	Revenue Recognition Deferred Revenue RevenueRecognitionDeferredRevenue	<div> <p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"> <b>Deferred Revenue</b></p> <p style="MARGIN-TOP: 6pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"> Cash received as prepayment on future services is deferred and recognized as revenue as the services are performed. The Company must remit interest on any deferred revenue related to a governmental agency. As of September 30, 2013 and December 31, 2012, no interest was due as the Company did not have any deferred revenue from a government agency.</p> </div>
	us-gaap	Revenues Revenues	1909471
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	617586
	us-gaap	Income Taxes Paid IncomeTaxesPaid	-13437
	us-gaap	Investment Income Interest InvestmentIncomeInterest	11589
	us-gaap	Excess Tax Benefit From Share Based Compensation Operating Activities ExcessTaxBenefitFromShareBasedCompensationOperatingActivities	0
	us-gaap	Operating Income Loss OperatingIncomeLoss	-18234017
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-18827388
	us-gaap	Interest Paid InterestPaid	-3317
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	3445315
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-49138
	us-gaap	Net Income Loss NetIncomeLoss	-18827388
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	33255
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	2398611
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3245585
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	40923196
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	1500000
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-1249992
	us-gaap	Share Based Compensation ShareBasedCompensation	282450
	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	20143488
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	28426484
	us-gaap	Interest Expense InterestExpense	604960
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	3985489
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	43941850
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	1466745
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	16897903
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	316827
	us-gaap	Depreciation Depreciation	15821
	ck0001567514	Percentage Of Dividend Rate PercentageOfDividendRate	0.00	pure
	ck0001567514	Proceeds From Common Stock Subscribed ProceedsFromCommonStockSubscribed	109834
	ck0001567514	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageRemainingContractualTerm	P1Y3M18D
	ck0001567514	License Expiration Periods LicenseExpirationPeriods	The later of expiration of the last licensed patent covering a licensed product, its method of manufacture or use, the expiration of other government grants providing market exclusivity or ten years after first commercial sale of a licensed product in such country, subject to rights of the parties to sooner terminate the agreement on certain events and the right of Takeda to unilaterally terminate the agreement upon a specified number of days' prior notice.
	ck0001567514	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Remaining Contractual Term2 ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm2	P6Y2M12D
	ck0001567514	Certificates Of Deposit Maturity Period CertificatesOfDepositMaturityPeriod	More than three months
	ck0001567514	Maturity Period Of Liquid Investments To Be Considered As Cash Equivalents MaturityPeriodOfLiquidInvestmentsToBeConsideredAsCashEquivalents	Three months or less
	ck0001567514	Share Based Compensation Arrangement By Share Based Payment Award Canceled Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardCanceledWeightedAverageRemainingContractualTerm	P8Y8M12D
	ck0001567514	Business Combination Share Exchange Ratio BusinessCombinationShareExchangeRatio	0.5	shares
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.75
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.75
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	5603575	shares
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-14776213
	us-gaap	Revenues Revenues	2449055
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-2099
	us-gaap	Income Taxes Paid IncomeTaxesPaid	-13857
	us-gaap	Investment Income Interest InvestmentIncomeInterest	29730
	us-gaap	Operating Income Loss OperatingIncomeLoss	-15436794
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-15431754
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	1000000
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-241534
	us-gaap	Net Income Loss NetIncomeLoss	-15431754
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	38957
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-738321
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	4911166
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2916139
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	7022
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	5950123
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-1249995
	us-gaap	Share Based Compensation ShareBasedCompensation	282629
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2078182
	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	17885849
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-9858025
CY2012Q3	us-gaap	Share Based Compensation ShareBasedCompensation	97461
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	14969710
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	7022
	us-gaap	Depreciation Depreciation	39413
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	24690
CY2012	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y4M24D
CY2012	us-gaap	Excess Tax Benefit From Share Based Compensation Operating Activities ExcessTaxBenefitFromShareBasedCompensationOperatingActivities	0
CY2012Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.40
CY2012Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.40
CY2012Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	5607022	shares
CY2012Q3	us-gaap	Revenues Revenues	377911
CY2012Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	6656
CY2012Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-2221571
CY2012Q3	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-2223145
CY2012Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	802053
CY2012Q3	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	2599482
CY2012Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1797429
CY2012Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	8230
CY2013Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.42
CY2013Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.42
CY2013Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	11779745	shares
CY2013Q3	us-gaap	Revenues Revenues	667955
CY2013Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	5626
CY2013Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-4785358
CY2013Q3	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-4911620
CY2013Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1295571
CY2013Q3	us-gaap	Share Based Compensation ShareBasedCompensation	119217
CY2013Q3	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	5453313
CY2013Q3	us-gaap	Interest Expense InterestExpense	131888
CY2013Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4157742
CY2013Q3	us-gaap	Depreciation Depreciation	4729

Files In Submission

Name	View Source	Status
0001193125-13-427801-index-headers.html	Edgar Link	pending
0001193125-13-427801-index.html	Edgar Link	pending
0001193125-13-427801.txt	Edgar Link	pending
0001193125-13-427801-xbrl.zip	Edgar Link	pending
ck0001567514-20130930.xml	Edgar Link	completed
ck0001567514-20130930.xsd	Edgar Link	pending
ck0001567514-20130930_cal.xml	Edgar Link	unprocessable
ck0001567514-20130930_def.xml	Edgar Link	unprocessable
ck0001567514-20130930_lab.xml	Edgar Link	unprocessable
ck0001567514-20130930_pre.xml	Edgar Link	unprocessable
d611955d10q.htm	Edgar Link	pending
d611955dex311.htm	Edgar Link	pending
d611955dex312.htm	Edgar Link	pending
d611955dex32.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ITCI
Intra-Cellular Therapies, Inc. Stock $itci

2013 Q4 Form 10-Q Financial Statement

#000119312513427801 Filed on November 05, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ITCI Intra-Cellular Therapies, Inc. Stock $itci

2013 Q4 Form 10-Q Financial Statement

#000119312513427801 Filed on November 05, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ITCI
Intra-Cellular Therapies, Inc. Stock $itci